Live biotherapeutic/Microbiome Based Therapeutics Market Size is valued at USD 73.25 Bn in 2024 and is predicted to reach USD 142.81 Bn by the year 2034 at a 7.04% CAGR during the forecast period for 2025-2034.
A live microbe is utilized in a Live Biotherapeutic product to treat, prevent, or cure a disease. Microorganisms that may be beneficial to health have been discovered as the human microbiome, and its relationship to human health has come to be better understood. These microorganisms have a lot of potential for use as Live Biotherapeutic products in clinical settings. Several clinical trials are being conducted to assess their potential as a treatment. LBPs are believed to have biological effects by modulating the host-microbiota rather than directly acting on known targets or distant organs, tissues, or receptors. Importantly, LBPs will have a biological effect by influencing the local ecosystem, other microorganisms, and their interactions with the host.
Throughout the forecast period, market growth is anticipated to be driven by rising research and development efforts, as well as an expanding pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases. The development of new drugs and clinical trial activities for the treatment of diseases are being aided by ongoing innovation and technological advancements.
In 2019, 4D pharma collaborated with MSD to research and develop Live Biotherapeutics for vaccines. 4D's proprietary MicroRx® platform will be combined with MSD's expertise in developing and commercializing novel vaccines. During the forecast period, significant growth opportunities are anticipated as government funding and the R&D budget for drug development both increases. Over 640 patents focused on microbiome therapeutics were approved in 2020. The complexities occur due to a lack of expertise, specialized infrastructure, the need for astronomical capital expenditures, capacity limitations, and restrictions on ensuring compliance with good manufacturing practices (GMP).
The Live Biotherapeutic Product Market is segmented into By Product Which consists of VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products. Whereas, By Target Disease Indication, the segmentation includes Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications. The segment Route Of Administration which includes Oral and Rectal Therapeutics. The Distribution Channel segment consists of Direct Sales, Pharmacies, Online Platforms. Whereas, By End User, the market is divided into Healthcare Facilities, Home Healthcare.
Regionally, North America is anticipated to experience brisk growth during the forecast period as a result of rising demand and the significant COVID-19 effect. Large sums of money are given to businesses to research Live Biotherapeutic ingredients and create new products.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 73.25 Bn |
|
Revenue Forecast In 2034 |
USD 142.81 Bn |
|
Growth Rate CAGR |
CAGR of 7.04% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Target Disease Indication, Route Of Administration, Distribution channel, end user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
4D Pharma, Adiso Therapeutics, Alveolus Bio Inc, AOBiome Therapeutics Inc, Assembly Biosciences, Azitra, Biomica, Destiny Pharma, Destiny Pharma plc, EnteroBiotix Limited, Finch Therapeutics, Infant Bacterial Therapeutics AB, MaaT Pharma, Microbiotica, OSEL Inc, OxThera, Scioto Biosciences Inc, Second Genome, Seres Therapeutics, Servatus Limited, Siolta Therapeutics, Vedanta Biosciences, YSOPIA Bioscience. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Live biotherapeutic/Microbiome Based Therapeutics Market By Product
Live biotherapeutic/Microbiome Based Therapeutics Market By Route Of Administration
Live biotherapeutic/Microbiome Based Therapeutics Market By Target Disease Indication
Live biotherapeutic/Microbiome Based Therapeutics Market By Distribution Channel
Live biotherapeutic/Microbiome Based Therapeutics Market By End User
Live biotherapeutic/Microbiome Based Therapeutics Market By Region
North America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Europe Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Latin America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
